Cholesteryl ester-transfer protein inhibitors stimulate aldosterone biosynthesis in adipocytes through nox-dependent processes

Journal of Pharmacology and Experimental Therapeutics

Volumn 353, Issue 1, 2015, Pages 27-34

  Rios, Francisco J ^a   Neves, Karla B ^b   Cat, Aurelie Nguyen Dinh ^a   Even, Sarah ^a   Palacios, Roberto ^c   Montezano, Augusto C ^a   Touyz, Rhian M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSIDAD REY JUAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE; ANACETRAPIB; CHEMERIN; CHOLESTEROL ESTER TRANSFER PROTEIN; CYTOCHROME P450; CYTOCHROME P450 11B1; DALCETRAPIB; HYDROGEN PEROXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 3; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; STAT3 PROTEIN; STEROIDOGENIC ACUTE REGULATORY PROTEIN; TORCETRAPIB; UNCLASSIFIED DRUG; OXAZOLIDINONE DERIVATIVE; QUINOLINE DERIVATIVE; THIOL DERIVATIVE;

ADIPOCYTE; ALDOSTERONE RELEASE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL LINE; DRUG EFFECTS; METABOLISM; PHOSPHORYLATION;

ADIPOCYTES; ALDOSTERONE; ANIMALS; CELL LINE; CHOLESTEROL ESTER TRANSFER PROTEINS; HUMANS; MICE; NADPH OXIDASE; OXAZOLIDINONES; PHOSPHORYLATION; QUINOLINES; REACTIVE OXYGEN SPECIES; STAT3 TRANSCRIPTION FACTOR; SULFHYDRYL COMPOUNDS;

EID: 84923346612     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.221002     Document Type: Article

References (28)

1. Alwan A, Maclean DR, Riley LM, d'Espaignet ET, Mathers CD, Stevens GA, and Bettcher D (2010) Monitoring and surveillance of chronic non-communicable diseases: progress and capacity in high-burden countries. Lancet 376:1861-1868.
2. Barter PJ, Brewer HB, Jr, Chapman MJ, Hennekens CH, Rader DJ, and Tall AR (2003) Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 23:160-167.
3. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, et al.; ILLUMINATE Investigators (2007) Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357:2109-2122.
4. Briones AM, Nguyen Dinh Cat A, Callera GE, Yogi A, Burger D, He Y, Corrêa JW, Gagnon AM, Gomez-Sanchez CE, Gomez-Sanchez EP, et al. (2012) Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 59:1069-1078.
5. Briones AM, Tabet F, Callera GE, Montezano AC, Yogi A, He Y, Quinn MT, Salaices M, and Touyz RM (2011) Differential regulation of Nox1, Nox2 and Nox4 in vascular smooth muscle cells from WKY and SHR. J Am Soc Hypertens 5:137-153.
6. Chang RL, Xie L, Xie L, Bourne PE, and Palsson BO (2010) Drug off-target effects predicted using structural analysis in the context of a metabolic network model. PLOS Comput Biol 6:e1000938.
7. Dalvie D, Chen W, Zhang C, Vaz AD, Smolarek TA, Cox LM, Lin J, and Obach RS (2008) Pharmacokinetics, metabolism, and excretion of torcetrapib, a cholesteryl ester transfer protein inhibitor, in humans. Drug Metab Dispos 36:2185-2198.
8. Forrest MJ, Bloomfield D, Briscoe RJ, Brown PN, Cumiskey AM, Ehrhart J, Hershey JC, Keller WJ, Ma X, McPherson HE, et al. (2008) Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 154:1465-1473.
9. Funder JW (2010) Aldosterone, sodium, and hypertension: lessons from torcetrapib? Hypertension 55:221-223.
10. Gordon T, Castelli WP, Hjortland MC, Kannel WB, and Dawber TR (1977) High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 62:707-714.
11. Gotto AM, Jr, Cannon CP, Li XS, Vaidya S, Kher U, Brinton EA, Davidson M, Moon JE, Shah S, Dansky HM, et al.; DEFINE Investigators (2014) Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. Am J Cardiol 113:76-83.
12. Hattangady NG, Olala LO, Bollag WB, and Rainey WE (2012) Acute and chronic regulation of aldosterone production. Mol Cell Endocrinol 350:151-162.
13. Hu X, Dietz JD, Xia C, Knight DR, Loging WT, Smith AH, Yuan H, Perry DA, and Keiser J (2009) Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology 150:2211-2219.
14. Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K, Maruhama Y, Mabuchi H, and Tall AR (1990) Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 323:1234-1238.
15. Johns DG, Duffy J, Fisher T, Hubbard BK, and Forrest MJ (2012) On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors. Drugs 72:491-507.
16. Kontush A, Guérin M, and Chapman MJ (2008) Spotlight on HDL-raising therapies: insights from the torcetrapib trials. Nat Clin Pract Cardiovasc Med 5:329-336.
17. Livak KJ and Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T)) Method. Methods 25:402-408.
18. Lüscher TF, Landmesser U, von Eckardstein A, and Fogelman AM (2014) Highdensity lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target. Circ Res 114:171-182.
19. Miller GJ and Miller NE (1975) Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1:16-19.
20. Rajamohan SB, Raghuraman G, Prabhakar NR, and Kumar GK (2012) NADPH oxidase-derived H (2) O (2) contributes to angiotensin II-induced aldosterone synthesisin human and rat adrenal cortical cells. Antioxid Redox Signal 17:445-459.
21. Robinson LB and Frishman WH (2014) Anacetrapib: a potential new therapy for dyslipidemia. Cardiol Rev 22:253-261.
22. Roheim PS (1986) Atherosclerosis and lipoprotein metabolism: role of reverse cholesterol transport. Am J Cardiol 57:3C-10C.
23. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, et al.; dal-OUTCOMES Investigators (2012) Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367:2089-2099.
24. Spyroglou A, Manolopoulou J, Wagner S, Bidlingmaier M, Reincke M, and Beuschlein F (2009) Short term regulation of aldosterone secretion after stimulation and suppression experiments in mice. J Mol Endocrinol 42:407-413.
25. Tall AR (1986) Plasma lipid transfer proteins. J Lipid Res 27:361-367.
26. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, Hindy G, Hólm H, Ding EL, Johnson T, et al. (2012) Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380:572-580.
27. Xie L, Li J, Xie L, and Bourne PE (2009) Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors. PLOS Comput Biol 5:e1000387.
28. Zhang K, Guo W, Yang Y, and Wu J (2011) JAK2/STAT3 pathway is involved in the early stage of adipogenesis through regulating C/EBPβ transcription. J Cell Biochem 112:488-497.